A
Anushka Patel
Researcher at The George Institute for Global Health
Publications - 337
Citations - 29250
Anushka Patel is an academic researcher from The George Institute for Global Health. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 69, co-authored 315 publications receiving 25272 citations. Previous affiliations of Anushka Patel include Northwestern University & Ministry of Health (New South Wales).
Papers
More filters
Journal ArticleDOI
Treatment and outcomes of acute coronary syndromes in women: An analysis of a multicenter quality improvement Chinese study.
TL;DR: Sex disparities were apparent in some key quality of care indicators for patients with suspected with ACS presenting to hospitals in China and the effects of a quality improvement program in Chinese male and female ACS patients.
Journal ArticleDOI
Lifestyle intervention programme for Indian women with history of gestational diabetes mellitus.
Deksha Kapoor,Yashdeep Gupta,Ankush Desai,Devarsetty Praveen,Rohina Joshi,Roya Rozati,Neerja Bhatla,Dorairaj Prabhakaran,Prasuna Reddy,Anushka Patel,Nikhil Tandon +10 more
TL;DR: This study showed feasibility of the lifestyle intervention delivered in group sessions to women with prior gestational diabetes mellitus, with 80% of women attending four or more sessions.
Journal ArticleDOI
EMPOWER: Toward the Global Dissemination of Psychosocial Interventions.
Vikram Patel,John A. Naslund,Sheena Wood,Anushka Patel,Joshua J. Chauvin,Ravindra Agrawal,Anant Bhan,Udita Joshi,Margaux Amara,Brandon A. Kohrt,Daisy R. Singla,Christopher G. Fairburn +11 more
TL;DR: The EMPOWER program leverages digital tools for training and supervising NSPs, designing competency-based curricula, assessing treatment-specific competencies, implementing measurement-based peer supervision for support and quality assurance, and evaluating impacts to enhance the effectiveness of the delivery system as discussed by the authors .
Journal ArticleDOI
ADVANCE: lessons from the run-in phase of a large study in type 2 diabetes.
TL;DR: A substantial fall in blood pressure was observed following 6 weeks of treatment with a fixed low-dose combination of perindopril-indapamide in a broad range of high-risk individuals with type 2 diabetes.
Journal ArticleDOI
New insights from ADVANCE.
TL;DR: The safety and efficacy of perindopril–indapamide in lowering blood pressure and of a gliclazide-MR-based regimen in loweringBlood glucose have been established with the completion of a 6-week run-in phase and of more than 4 years of post-randomization follow-up.